Product
Supplier
Encyclopedia
Inquiry
Home > News > Policy & Regulation > Glenmark receives ANDA approval for steroidal drug from US FDA

Glenmark receives ANDA approval for steroidal drug from US FDA

ECHEMI 2018-10-17

Glenmark Pharmaceuticals Inc., USA has been granted final approval by the US FDA for Estradiol Vaginal Inserts USP, 10 mcg, the generic version of Vagifem1, 10 mcg, of Novo Nordisk Inc.

According to IQVIA sales data for the 12-month period ending July 2018, the Novo Nordisk product achieved annual sales of approximately $286.3-mn.

Glenmark’s current portfolio consists of 139 products authorized for distribution in the US market and 61 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Disclaimer: ECHEMI reserves the right of final explanation and revision for all the information.
Comment
Comment

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.